Synapse - Mark Robson

Results (682)

Four-year follow-up of outcomes following risk-reducing salpingo-oophorectomy in ORCA mutation carriers

Meeting Abstract

Kemel, Y.; Kauff, N. D.; Robson, M. E.; Goldfrank, D. J.; Wadsworth, E.; Diiorio, T.; Boyd, J.; Hudis, C. A.; Barakat, R. R.; Offit, K.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

Association of personal and family history with decision to undergo risk-reducing salpingo-oophorectomy in BRCA mutation carriers

Meeting Abstract

Kauff, N. D.; Wadsworth, E.; Goldfrank, D. J.; Robson, M. E.; Lee, J.; Lafaro, K.; Aaron, S.; Norton, L.; Barakat, R. R.; Offit, K.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

A prospective longitudinal study of the impact of adjuvant chemotherapy for breast cancer (BC) on older patients' functional status and quality of life

Meeting Abstract

Hurria, A.; Panageas, K.; Zuckerman, E.; Fornier, M.; D'Andrea, G.; Dang, C.; Moasser, M.; Robson, M.; Seidman, A.; Currie, V.; more...
Breast Cancer Research and Treatment (2005)

Fulltext@MSK | Save

Adherence to mammogram (MMG) screening guidelines in BRCA1/2 mutation carriers

Meeting Abstract

Goldfrank, D. J.; Lee, J.; Kauff, N. D.; Hurley, K. E.; Balistreri, L. M.; Hellawell, J.; Borgen, P. I.; Hudis, C. A.; Offit, K.; Robson, M. E.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

Radiation exposure and breast cancer risk for BRCA mutation carriers

Meeting Abstract

Goldfrank, D. J.; Chuai, S.; Cajal, T. R. Y.; Lee, J. B.; Alonso, M. C.; Diez, O.; Baiget, M.; Kauff, N. D.; Offit, K.; Bernstein, J. L.; more...
Breast Cancer Research and Treatment (2005)

Fulltext@MSK | Save

Increased dose-density (DD) is feasible: A pilot study of epirubicin and cyclophosphamide (EC) followed by paclitaxel (T), at 10-11 day interval with filgrastim support, for women with early breast carcinoma (BC)

Meeting Abstract

Fornier, M. N.; Seidman, A. D.; Lake, D.; D'Andrea, G.; Bromberg, J.; Robson, M.; Van Poznak, C. H.; Panageas, K.; Norton, L.; Hudis, C.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

Prolonged dose-dense (DD) epirubicin and cyclophosphamide (EC) followed by paclitaxel (T) in breast cancer (BCA) is feasible

Meeting Abstract

Dang, C.; Smith, K.; Lake, D.; Fornier, M.; D'Andrea, G.; Seidman, A.; Sklarin, N.; Troso-Sandoval, T.; Sugarman, S.; Gilewski, T.; more...
Breast Cancer Research and Treatment (2005)

Fulltext@MSK | Save

Preliminary cardiac safety results of dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2/neu overexpressed/amplified breast cancer (BCA)